CAAS
ONCY

Capital Asset Advisory Services’s Oncolytics Biotech ONCY Stock Holding History

Capital Asset Advisory Services’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-250
Closed -$1K – 1246
2020
Q4 		$1K Buy
+250
New +$599 ﹤0.01% 1531

Other funds holding ONCY

IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Asset Advisory Services's ONCY Position: Q1 2021 in Review

Capital Asset Advisory Services sold out of Oncolytics Biotech (ONCY) in Q1 2021, closing a stake of 250 shares — an estimated $1K sold.

Capital Asset Advisory Services first reported a position in ONCY in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 41 funds tracked by Wall St. Rank hold ONCY as of Q1 2021.

  • Capital Asset Advisory Services reported no remaining Oncolytics Biotech position as of Q1 2021 after selling out during the quarter.
  • Capital Asset Advisory Services sold 250 Oncolytics Biotech shares in Q1 2021, an estimated $1K.
  • Capital Asset Advisory Services first reported a position in Oncolytics Biotech in Q4 2020 and held it in 1 quarter.
  • Capital Asset Advisory Services's Oncolytics Biotech position peaked at $1K in Q4 2020.
  • 41 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2021.

Based on Capital Asset Advisory Services's 13F filing for Q1 2021, filed 13 May 2021.